Pfizer’s 7.1% forward dividend yield demands 2,907 shares to generate $5,000 yearly, amid patent expirations and strategic acquisitions.
Investors need 2,907 shares of Pfizer, or about $69,940 at current prices, to earn $5,000 annually from its $0.43 quarterly dividend. The drugmaker’s 7.1% forward yield stands out among blue chips but faces risks from looming patent expirations on key drugs like Eliquis and Prevnar 13.
Patent losses threaten roughly one-third of Pfizer’s revenue within two years. The company has countered by acquiring firms like Seagen and Biohaven, bolstering its oncology and anti-obesity pipelines. These moves aim to offset revenue declines but depend on successful commercialization.
Pfizer’s dividend sustainability remains a focus for income investors, given its high yield and strategic shifts. Market reaction has been muted as investors weigh near-term risks against long-term growth potential.